PMID- 27779169
OWN - NLM
STAT- MEDLINE
DCOM- 20170313
LR  - 20220311
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 129
IP  - 21
DP  - 2016 Nov 5
TI  - Comparison of the 1-year Outcomes of Conbercept Therapy between Two Different 
      Angiographic Subtypes of Polypoidal Choroidal Vasculopathy.
PG  - 2610-2616
LID - 10.4103/0366-6999.192779 [doi]
AB  - BACKGROUND: Polypoidal choroidal vasculopathy (PCV) is characterized by the 
      presence of polyps with or without a branching vascular network and more 
      prevalent among Asians. The aim of this study was to compare the outcomes of 
      conbercept therapy between two different angiographic subtypes of PCV. METHODS: 
      Fifty-eight patients of PCV were classified into two phenotypes according to 
      indocyanine green angiography (ICGA). In Type 1, both feeder and draining vessels 
      are visible on ICGA and network vessels are numerous. In Type 2, neither feeder 
      nor draining vessels are detectable, and the number of network vessels is small. 
      The patients were treated with intravitreal conbercept (IVC) for 3 months. 
      Additional IVC was given at subsequent monthly visits, if needed. The patients 
      were followed up for 12 months, and changes in mean best-corrected visual acuity 
      (BCVA), central retinal thickness (CRT), subretinal fluid (SRF) thickness, 
      pigmented epithelial detachment (PED), hemorrhage, and number of polypoidal 
      lesions were evaluated. RESULTS: The mean BCVA in Type 2 PCV (15.92 +/- 9.76 
      letters) achieved a significantly greater improvement than that in the Type 1 
      (14.10 +/- 9.07 letters) at month 12 (t = 2.37, P< 0.01). Moreover, the mean CRT 
      decrease was numerically greater in Type 2 (120.44 +/- 73.81 mum) compared with Type 
      1 (106.48 +/- 72.33 mum) at month 6 (t = 4.31, P< 0.01), and greater in Type 2 
      (130.21 +/- 76.28 mum) compared with Type 1 (111.67 +/- 79.57 mum) at month 9 (t = 
      1.87, P< 0.01). There was no significant difference between the two types for the 
      decrease in SRF thickness, PED height, and regression of polyps from month 3 to 
      12 (t = 2.97, P > 0.05). CONCLUSION: Classification systems for PCV will show 
      differences in presentation, natural history, or response to anti-vascular 
      endothelial growth factor treatment and might, therefore, provide a new key to 
      the choice of treatment for the disease.
FAU - Cheng, Yong
AU  - Cheng Y
AD  - Department of Ophthalmology, Peking University People's Hospital, Beijing 100044; 
      Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 
      100044; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid 
      Diseases, Beijing 100044, China.
FAU - Shi, Xuan
AU  - Shi X
AD  - Department of Ophthalmology, Peking University People's Hospital, Beijing 100044; 
      Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 
      100044; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid 
      Diseases, Beijing 100044, China.
FAU - Qu, Jin-Feng
AU  - Qu JF
AD  - Department of Ophthalmology, Peking University People's Hospital, Beijing 100044; 
      Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 
      100044; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid 
      Diseases, Beijing 100044, China.
FAU - Zhao, Ming-Wei
AU  - Zhao MW
AD  - Department of Ophthalmology, Peking University People's Hospital, Beijing 100044; 
      Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 
      100044; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid 
      Diseases, Beijing 100044, China.
FAU - Li, Xiao-Xin
AU  - Li XX
AD  - Department of Ophthalmology, Peking University People's Hospital, Beijing 100044; 
      Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 
      100044; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid 
      Diseases, Beijing 100044, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
SB  - IM
MH  - Aged
MH  - Choroid/physiopathology/*surgery
MH  - Choroidal Neovascularization/physiopathology/*surgery
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Care
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Visual Acuity/physiology
PMC - PMC5125341
EDAT- 2016/10/26 06:00
MHDA- 2017/03/14 06:00
PMCR- 2016/11/05
CRDT- 2016/10/26 06:00
PHST- 2016/10/26 06:00 [pubmed]
PHST- 2017/03/14 06:00 [medline]
PHST- 2016/10/26 06:00 [entrez]
PHST- 2016/11/05 00:00 [pmc-release]
AID - ChinMedJ_2016_129_21_2610_192779 [pii]
AID - CMJ-129-2610 [pii]
AID - 10.4103/0366-6999.192779 [doi]
PST - ppublish
SO  - Chin Med J (Engl). 2016 Nov 5;129(21):2610-2616. doi: 10.4103/0366-6999.192779.